



## Article

# Biofunctionalized Nanostructured Yttria Modified Non-Invasive Impedometric Biosensor for Efficient Detection of Oral Cancer

Suveen Kumar <sup>1,2</sup>, Shweta Panwar <sup>1</sup>, Saurabh Kumar <sup>1</sup>, Shine Augustine <sup>1</sup>  
and Bansi D. Malhotra <sup>1,\*</sup>

<sup>1</sup> Nanobioelectronics Laboratory, Department of Biotechnology, Delhi Technological University, Delhi110042, India

<sup>2</sup> Department of Chemistry, University of Delhi, Delhi110007, India

\* Correspondence: bansi.malhotra@gmail.com

Received: 4 July 2019; Accepted: 17 August 2019; Published: 22 August 2019

**Abstract:** We report results of the studies relating to the development of an efficient biosensor for non-invasive detection of CYFRA-21-1 cancer biomarker. We used a low dielectric constant material (nanostructured yttrium oxide,  $\text{nY}_2\text{O}_3$ ) for the fabrication of the biosensing platform. The  $\text{nY}_2\text{O}_3$  was synthesized via solvothermal process and functionalized using 3-aminopropyl triethoxy silane (APTES). Electrophoretic deposition (EPD) of the functionalized nanomaterial (APTES/ $\text{nY}_2\text{O}_3$ ) onto an indium tin oxide (ITO)-coated glass electrode was conducted at a DC potential of 50V for 60s. The EDC-NHS chemistry was used for covalent immobilization of  $-\text{COOH}$  bearing monoclonal anti-CYFRA-21-1 onto  $-\text{NH}_2$  groups of APTES/ $\text{nY}_2\text{O}_3$ /ITO electrode. To avoid the non-specific interaction on the anti-CYFRA-21-1/APTES/ $\text{nY}_2\text{O}_3$ /ITO immunoelectrode, bovine serum albumin (BSA) was used. X-ray diffraction (XRD), transmission electron microscopy (TEM), and field emission scanning electron microscopy (FESEM) were utilized for structural and morphological studies, whereas Fourier-transform infrared spectroscopy (FTIR) was used for the bonding analysis. Cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) techniques were used for electrochemical characterization and response studies of fabricated electrodes. The fabricated immunosensor (BSA/anti-CYFRA-21-1/APTES/ $\text{nY}_2\text{O}_3$ /ITO) exhibited linearity in the range of  $0.01\text{--}50\text{ ng}\cdot\text{mL}^{-1}$ , sensitivity of  $226.0\text{ }\Omega\cdot\text{mL}\cdot\text{ng}^{-1}$ , and lower detection limit of  $0.01\text{ ng}\cdot\text{mL}^{-1}$ . A reasonable correlation was observed between the results obtained using this biosensor and concentration of CYFRA-21-1 measured through ELISA (enzyme-linked immunosorbent assay) technique in salivary samples of oral cancer patients.

**Keywords:** non-invasive; dielectric constant; yttrium oxide; metal oxide; nanoparticles; CYFRA-21-1

## 1. Introduction

Cancer is an abnormal and uncontrolled cell growth [1,2]. According to a WHO report, cancer is currently the secondmost death-causing disease worldwide and about 8.8 million deaths were reported in 2015 due to cancer [3]. Lung, colon, breast, prostate, oral, and ovarian cancers are the most prominent cancers in the present-day world. Oral cancer (OC) is the sixthmost death-causing cancer and it can occur in lips, cheeks, gingiva, or palate part in the mouths of human beings. The main reason behind oral cancer is the mutation, which occurs at the gene level due to which uncontrolled cell cycle and differentiation do not take place [4]. Mutations in a gene may occur due to the use of a mutagenic agent which is widely present in tobacco, cigarettes, cigars, alcohol, etc. [5] The current detection techniques such as biopsy, cytopathology, visualization adjuncts, etc. can be used for detection of OC at advanced stages [6–9]. Moreover, these techniques require a tissue

sample for analysis, and hence are invasive, time-consuming, expensive, and require trained experts for sample collection as well as data analysis. To overcome these limitations, non-invasive [10] biosensors can play an important role since they offer many advantages such as painless detection, high sensitivity, cost-effectiveness, and require low sample volume.

For a non-invasive biosensor, salivary CYFRA-21-1 biomarker can be used for OC detection [11,12]. Kumar et al. recently used a number of materials including zirconia, hafnia, and nanocomposites for development of non-invasive biosensors. Tiwari et al. used lanthanum hydroxide for the fabrication of a biosensor for CYFRA-21-1 detection via CV or DPV (differential pulse voltammetry) techniques [13–18]. In these methods, even a slight change in volume of a biological sample and analytical solution can adversely affect the peak current response. Besides this, the accurate determination of active surface area of the immunoelectrode is an important issue. These limitations can, perhaps, be overcome by using an EIS technique.

In the fabrication of a biosensor, nanostructured metal oxides (NMOs), nanostructured metal sulfides (NMSs), reduced graphene oxide, carbon nanotubes, etc. have been extensively used as immobilization matrices [19–26]. The nanostructured oxides of metals (e.g. magnesium oxide, zinc oxide, molybdenum trioxide, hafnia, titania, zirconia, etc.) have been found to have fascinating nano-morphological, functional, biocompatible, and electrochemical properties, and enhanced electron-transfer kinetics [19,27–33]. Among these NMOs, the nano-sized yttrium oxide (Yttria,  $nY_2O_3$ ) exhibits high surface-to-volume ratio, fast oxygen ion mobility, efficient charge transfer ability, chemical inertness, sharp line emission bands, and biocompatibility [34–36]. In addition, it is known to have high quantum yield, excellent photo stability, and low dielectric constant ( $k$ ), making it a potential candidate for application towards the development of biosensors [37–41]. The low dielectric constant (13) of yttrium oxide makes the thin film highly conductive [42]. Besides this, the oxygen moieties in  $Y_2O_3$  can facilitate functionalization and covalent immobilization of antibodies. Rasheed et al. developed yttria-reduced graphene oxide nanocomposite based genosensor for detection of BRCA 1 (breast cancer) gene [40]. Efforts have also been made to use yttria–zirconia nanocomposite for the fabrication of sensors that can be used for detection of hydrogen, oxygen, and nitric oxide [41,43].

In this paper, we report results of the systematic studies relating to the development of a low dielectric material ( $nY_2O_3$ )-based electrochemical impedometric biosensor for detection of the salivary CYFRA-21-1 biomarker for OC detection. This immunosensor (BSA/anti-CYFRA-21-1/APTES/ $nY_2O_3$ /ITO) exhibits higher linear range (0.01–50  $ng \cdot mL^{-1}$ ) with remarkable sensitivity (226.0  $\Omega \cdot mL \cdot ng^{-1}$ ).

## 2. Experimental Section

### 2.1. Preparation and Functionalization of Nanostructured Yttrium Oxide ( $nY_2O_3$ )

Solvothermal synthesis process of nanoparticles was used for the synthesis of  $nY_2O_3$ . Initially, we separately prepared 4 mM of yttrium (III) nitrate hexahydrate, 2 mM of CTAB, and 80 mM of urea in Milli-Q water. The CTAB solution was added dropwise into yttrium (III) nitrate hexahydrate solution at 40 °C with constant stirring of 300 rpm for 2 h. Subsequently, urea was added dropwise into this solution at the same temperature and stirring conditions. Further, the whole solution was transferred to a hot (80 °C) ultrasonication bath for 2 h. The obtained precipitate was washed three times with Milli-Q water, followed by ethanol with the help of a centrifuge at 4500 rpm for 30 min, after which the precipitate was kept in a hot air oven at 80 °C to make it moisture-free. The dried product was transferred into the muffle furnace at 800 °C for 2 h. The obtained white product was crushed using a pestle and mortar and was stored in a desiccator at room temperature.


For functionalization of  $nY_2O_3$  with APTES molecules, 100 mg of  $nY_2O_3$  was dissolved in a minimal amount of isopropanol and then sonicated for 30 min. The solution was kept at constant stirring (300 rpm) at 50 °C until the nanoparticles were completely dispersed, after which we added 1 mL of APTES dropwise and 5 mL of Milli-Q water. This solution was kept in a magnetic stirrer at 200 rpm at 40 °C for 48 h. Subsequently, the solution mixture was washed with Milli-Q water (4500

rpm for 15 min) to remove any unbound APTES molecules. After centrifugation, the obtained powder was kept in a hot air oven at 50 °C until a moisture-free product was obtained.

## 2.2. Fabrication of Impedometric Biosensing Platform

A colloidal suspension of functionalized nanomaterial (APTES/nY<sub>2</sub>O<sub>3</sub>; concentration of 0.5 mg·mL<sup>-1</sup>) in acetonitrile was prepared via ultrasonication. Thereafter, 10 mL of colloidal solution was poured into a two-electrodes system (platinum as reference and ITO as working electrode), kept 1 cm apart to each other. Further, the optimized DC potential of 50V was applied in the two-electrodes system using an electrophoretic deposition (EPD) unit for 60s. The uniform thin layer of APTES/nY<sub>2</sub>O<sub>3</sub> was obtained on ITO electrode.

Immobilization of the monoclonal antibodies (anti-CYFRA-21-1) was carried onto APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode via EDC-NHS coupling chemistry. For this purpose, we took 15 µL of anti-CYFRA-21-1 and mixed it with 7.5 µL of 0.4 M of EDC and 7.5 µL of 0.1 M NHS, and uniformly drop cast onto APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode. This process helped in covalent bond formation between -COOH and -NH<sub>2</sub> group present on anti-CYFRA-21-1 and APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode, respectively. Subsequently, the fabricated platform (anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO) was washed with PBS to remove any unbound antibodies. For blocking of non-specific binding sites of the prepared electrode, we spread 30 mL of BSA (1 mg·dL<sup>-1</sup>) molecule. Finally, the fabricated immunoelectrodes (BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO) were stored at 4 °C. Scheme 1 shows the stepwise fabrication process of the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO biosensor.



**Scheme 1.** Stepwise fabrication process of the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO biosensor.

## 2.3. Biocompatibility Studies of nY<sub>2</sub>O<sub>3</sub>

The biocompatibility study of nY<sub>2</sub>O<sub>3</sub> was carried out on HEK 293 cell line by using MTT colorimetric assay technique. In this technique, the yellow color of MTT dye got converted into purple color of the formazan product by mitochondrial succinate dehydrogenase enzyme present in the live cells. The colored formazan product was solubilized in a buffer, and further, intensity of color was measured at 540 nm by using an ELISA plate reader.


For biocompatibility assay, 96-well plates were used. First of all, we seeded the HEK 293 cells (cell density as 105 cells per well) in a 96-well plate and incubated it at 37 °C in a humidified 5% CO<sub>2</sub> incubator. After the cells attained 70% confluence, we added 10 mg·mL<sup>-1</sup> to 250 mg·mL<sup>-1</sup> of nY<sub>2</sub>O<sub>3</sub> and again incubated it for 48 h in a CO<sub>2</sub> incubator. For the MTT assay, 200 µL of MTT solution (0.5 mg mL<sup>-1</sup> in DMEM) was added to each well and incubated for 2h. Further supernatant aspirated and the buffer (100 µL isopropanol containing 0.06M HCl and 0.5% SDS) were added to each well to

solubilize the formazan crystals. With the help of an ELISA plate reader, we measured the absorbance of colored product obtained at 540 nm. The untreated cells were taken as control with 100% viability and wells with MTT reagent without cells were used as blank to calibrate the spectrophotometer to zero absorbance. The relative cell viability (%) compared to control cells was calculated using  $[\text{abs}]_{\text{sample}}/[\text{abs}]_{\text{control}} \times 100$ . All the experiments were carried out in triplicate.

### 3. Results and Discussion


#### 3.1. Structural and Morphological Studies

To investigate the structural and morphological characteristics of synthesized  $\text{nY}_2\text{O}_3$  and the modified ITO electrodes, we conducted XRD, FESEM, and TEM studies. The obtained XRD pattern of the material is shown in Figure 1a. The diffraction peaks found at  $2\theta$  angle of 20.5, 29.2, 33.9, 40.0, 43.6, 48.5, 57.7, and 78.7 corresponded to the planes of (211), (222), (400), (332), (134), (440), (622), and (662), respectively. These peaks are in good correlation with the JCPDS NO. 65-3178, indicating successful synthesis of  $\text{Y}_2\text{O}_3$  with a crystalline size ( $D$ )  $\sim 80$  nm, calculated using the Debye Scherer method[14]. To confirm the size of the synthesized nanostructured material, we carried out TEM analysis at different magnifications (Figure 1b–d) and found that the synthesized nanomaterial was oval-shaped and had an average size of  $\sim 80$  nm. The FESEM technique (Figure 2) was used at different magnifications to investigate the morphology at the surface of (i)  $\text{nY}_2\text{O}_3$ , (ii) electrophoretically deposited APTES/ $\text{nY}_2\text{O}_3$ , and (iii) anti-CYFRA-21-1/APTES/ $\text{nY}_2\text{O}_3$  electrodes. The images (Figure 2a–c) observed at different magnifications confirm the presence of nanosized yttria, and these results are in agreement with the results of XRD and TEM studies. Further, in Figure 2d–f, the uniform deposition of APTES/ $\text{nY}_2\text{O}_3$  onto the ITO electrode can be seen. Interestingly, the globular morphology with uniform pattern (dendritic-like) was observed (Figure 2e–g) after immobilization of the anti-CYFRA-21-1.



**Figure 1.** (a) XRD graph of  $\text{nY}_2\text{O}_3$ . TEM images of  $\text{nY}_2\text{O}_3$  at scale bar of (b) 500 nm, (c) 200 nm, and (d) 50 nm.






**Figure 2.** FE-SEM images of  $nY_2O_3$  at (a)  $1\mu m$ , (b)  $200\text{ nm}$ , and (c)  $100\text{ nm}$ ; APTES/ $nY_2O_3$ /ITO at (d)  $1\mu m$ , (e)  $200\text{ nm}$ , and (f)  $100\text{ nm}$ ; and anti-CYFRA-21-1/APTES/ $nY_2O_3$ /ITO at (g)  $1\mu m$ , (h)  $200\text{ nm}$ , and (i)  $100\text{ nm}$ .

### 3.2. Fourier Transform-Infrared (FTIR) Spectroscopy Study


To investigate the presence of functional groups and bonds at the surfaces of APTES/ $nY_2O_3$ /ITO and anti-CYFRA-21-1/APTES/ $nY_2O_3$ /ITO electrodes, FTIR studies were conducted and the results are shown in Figure 3a and Figure 3b, respectively. In Figure 3a, the band present at  $1340\text{ cm}^{-1}$  is due to the presence of C–N, and  $1530\text{ cm}^{-1}$  is assigned to the presence of N–H (primary and secondary) bond present in amine molecules of the APTES-functionalized  $nY_2O_3$ [44]. The bands present between  $3000$  to  $4000\text{ cm}^{-1}$  are attributed to the N–H stretching of amine, C–H molecules present in APTES, and O–H molecules present in PBS[44]. These results confirm the presence of amine ( $-NH_2$ ) group onto the APTES/ $nY_2O_3$ /ITO electrode. Further, we investigated the formation of amide bond after the immobilization of anti-CYFRA-21-1 onto APTES/ $nY_2O_3$ /ITO electrode (Figure 3b). In Figure 3b, the presence of band at  $1260\text{ cm}^{-1}$  confirms the formation of C–N (amide) bond between  $-COOH$  group present at the Fc region of the anti-CYFRA-21-1 and  $-NH_2$  groups of APTES/ $nY_2O_3$ /ITO electrode[44]. The bands seen at  $1560\text{ cm}^{-1}$  and  $1632\text{ cm}^{-1}$  indicate the presence of N–H (primary and secondary) bending and C=O groups of amides. Bands found at  $1055\text{ cm}^{-1}$  and  $1095\text{ cm}^{-1}$  are attributed to the C–O bands of carboxylic acid group, and bands present at  $3350\text{ cm}^{-1}$  are assigned to the presence of N–H band of amines and O–H groups of PBS[44]. The FTIR results confirm the covalent immobilization (amide bond formation) of anti-CYFRA-21-1 onto the APTES/ $nY_2O_3$ /ITO electrode.



**Figure 3.** FTIR data of (a) APTES/nY<sub>2</sub>O<sub>3</sub>/ITO and (b) anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode.

### 3.3. Biocompatibility Studies

The biocompatibility studies of nanomaterials are known to provide an insight towards the method of immobilization and facilitate the selection of nanomaterial for development of implantable chip [15]. Besides this, biocompatible nanomaterials can be helpful in providing a favorable environment for immobilized biomolecules. We performed the biocompatibility study through MTT assay and the results are shown in Figure 4 and Table S1. The cell viability of HEK 293 cells was more than 95% upto 50 µg mL<sup>-1</sup> concentration of nY<sub>2</sub>O<sub>3</sub>, after which the cell viability was found to be decreased. These results indicated that the synthesized nanomaterial (nY<sub>2</sub>O<sub>3</sub>) was favorable for the immobilization of biomolecules to be utilized for the fabrication of biosensors.




**Figure 4.** (i) Percentage of cell viability and (ii–ix) morphological view of HEK 293 cell line with various concentrations of nY<sub>2</sub>O<sub>3</sub>.

### 3.4. Electrochemical Characterization

Electrochemical investigations were carried out via EIS and CV studies using a redox mediator [Fe(CN)<sub>6</sub>]<sup>3-/4-</sup> (5 mM) in PBS. The effect of pH on the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrode was conducted via CV. The maximum activity of the immunoelectrode was observed at pH 7.0 [{Fe(CN)<sub>6</sub>]<sup>3-/4-</sup> (5 mM) in PBS buffer]. In both acidic and basic pH, the peak current

decreased (Figure 5i). This result was ascribed to the maximum activity of anti-CYFRA-21-1 at pH 7.0 of PBS. In both acidic and basic pH, the antibodies became denatured, resulting in a decrease of the peak current[14,45].



**Figure 5.** (i) CV studies of the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrode on different pH of [Fe(CN)<sub>6</sub>]<sup>3-/4-</sup>-containing PBS; (ii) electrochemical response of the different electrodes; (iii) CV response of APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode; and (iv) the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrode as a function of scan rate (50–150 mV/s). In both images, inset (a) magnitude of anodic ( $I_{pa}$ ) and cathodic ( $I_{pc}$ ) peak current as a function of scan rate (mV/s), and inset (b) difference potential  $\Delta E_p = E_{pa} - E_{pc}$  as a function of scan rate.

The electrochemical studies of the ITO, APTES/nY<sub>2</sub>O<sub>3</sub>/ITO, anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO, and BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrodes were investigated via CV. The peak current of the hydrolyzed ITO and APTES/nY<sub>2</sub>O<sub>3</sub> electrodes was found to be ~0.9 mA and ~0.7 mA, respectively (Figure 5ii). After immobilization of the antibodies and BSA, the peak current decreased to ~0.68 mA and ~0.66 mA, respectively. This decrease in peak current was attributed to the insulating properties of the biomolecules (anti-CYFRA-21-1 and BSA)[46]. The results of scan rate studies of the APTES/nY<sub>2</sub>O<sub>3</sub>/ITO and BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrodes carried out from 50 to 150 mV/s revealed that the fabricated immunoelectrode showed uniform electrochemical behavior (Figure 5iii,iv).

The cathodic and anodic peak current increased linearly towards the higher positive and lower negative potential, respectively (Inset i, Figure 5iii,iv and Figure S1). The observed linearity with respect to the scan rate revealed that the fabricated electrodes exhibited diffusion control process, indicating that we can use scan rate in the range, 50 to 150 mV/s for the desired electrochemical studies. Equations (1)–(4) well describe the linearity obtained between cathodic and anodic peak current response with respect to scan rate[13,30].

$$I_1 = [3.53 \mu\text{A}(\text{s mV}^{-1}) \times (\text{scan rate}[\text{mV s}^{-1}])] + 562.91 \mu\text{A}, R^2 = 0.987 \quad (1)$$

$$I_2 = [2.62 \mu\text{A}(\text{s mV}^{-1}) \times (\text{scan rate}[\text{mV s}^{-1}])] - 520.36 \mu\text{A}, R^2 = 0.985 \quad (2)$$

$$I_3 = [3.47 \mu\text{A}(\text{s mV}^{-1}) \times (\text{scan rate}[\text{mV s}^{-1}])] + 542.9 \mu\text{A}, R^2 = 0.989 \quad (3)$$

$$I_4 = [2.52 \mu\text{A}(\text{s mV}^{-1}) \times (\text{scan rate}[\text{mV s}^{-1}])] - 465.64 \mu\text{A}, R^2 = 0.987 \quad (4)$$

where  $I_1$  and  $I_3$  are the cathodic peak current of APTES/nY<sub>2</sub>O<sub>3</sub>/ITO and BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO;  $I_2$  and  $I_4$  are the anodic peak current of APTES/nY<sub>2</sub>O<sub>3</sub>/ITO and BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode, respectively. Furthermore, it was observed that the difference between the peak potential of the cathode and anode of the APTES/nY<sub>2</sub>O<sub>3</sub>/ITO and BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrodes exhibited a linear relationship with respect to the scan rate (Inset ii, Figure 5 iii,iv) and followed Equations (5) and (6).

$$\Delta E_1 = [0.006 \text{ V}(\text{s/mV}) \times (\text{scan rate}[\text{mV/s}])] + 1.08 \text{ V}, R^2 = 0.987 \quad (5)$$

$$\Delta E_2 = [0.006 \text{ V}(\text{s/mV}) \times (\text{scan rate}[\text{mV/s}])] + 1.01 \text{ V}, R^2 = 0.988 \quad (6)$$

where  $\Delta E_1$  and  $\Delta E_2$  reveal differences in peak potential of APTES/nY<sub>2</sub>O<sub>3</sub>/ITO and BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO, respectively.

The diffusion coefficient “D” of the electrode was calculated via RandlesSevick equation[17,47]:

$$I_p = (2.69 \times 10^5) n^{3/2} A D^{1/2} C v^{1/2} \quad (7)$$

where  $I_p$  is the peak current of the electrode,  $n$  is the number of electrons transferred in the redox reaction ( $n = 1$ ),  $A$  is the surface area of the electrode ( $0.25 \text{ cm}^2$ ),  $C$  is the concentration of the redox species ( $5 \times 10^{-3} \text{ mol} \cdot \text{cm}^{-2}$ ), and  $v$  is the scanning rate ( $50 \text{ mV} \cdot \text{s}^{-1}$ ). The “D” value at each step of electrode fabrication was determined to be  $9.68 \times 10^{-11} \text{ cm}^2 \cdot \text{s}^{-1}$  (APTES/nY<sub>2</sub>O<sub>3</sub>/ITO),  $9.18 \times 10^{-11} \text{ cm}^2 \cdot \text{s}^{-1}$  (anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO), and  $8.55 \times 10^{-11} \text{ cm}^2 \cdot \text{s}^{-1}$  (BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO), respectively. The diffusion coefficient of the fabricated immunoelectrode was found to be lower as compared to the value of diffusion coefficient as  $1.12 \times 10^{-3} \text{ cm}^2/\text{s}$  [13],  $2.12 \times 10^{-3} \text{ cm}^2/\text{s}$  [15], and  $0.62 \times 10^{-3} \text{ cm}^2/\text{s}$  [16]) for reported immunoelectrodes, indicating that the nY<sub>2</sub>O<sub>3</sub> was a more efficient nanomaterial for the fabrication of a cancer biosensor.

Quantification of antibodies onto the fabricated biosensing electrode surface are known to provide a better insight into the functioning of a biosensor, and it can be calculated by using Brown-Anson equation (Equation(8))[16].

$$I_p = n^2 F^2 \gamma A v (4RT)^{-1} \quad (8)$$

where  $I_p$  represents the peak current;  $A$  is the surface area of the electrode (we have taken  $0.25 \text{ cm}^2$  active surface area for performing the electrochemical characterization and response studies);  $v$  is the scan rate ( $\text{V/s}$ );  $\gamma$  is the surface concentration of the absorbed electro-active species;  $F$  is the Faraday constant;  $R$  is the gas constant; and  $T$  is room temperature. The number of antibodies immobilized onto the fabricated immunoelectrode was found to be  $5.91 \times 10^{-8} \text{ mol/cm}^2$ , which was higher as compared to the reported biosensing platforms for CYFRA-21-1 detection [16]. Kumar et al. [13] indicating that nY<sub>2</sub>O<sub>3</sub> provided better conjugation of biomolecules, leading to enhanced biosensing characteristics.


### 3.5. Electrochemical Impedometric Response, Control, Interferent, Reproducibility, and Shelf Life Studies

EIS is an important electrochemical technique that can be used to investigate the dynamics of antigen-antibodies interactions. We conducted EIS measurements using a three-electrode system in the frequency range from  $0.01$  to  $10^5 \text{ Hz}$  at a potential of  $0.10 \text{ V}$ . The impedometric response obtained between fabricated immunoelectrode and CYFRA-21-1 can be understood by using Nyquist plot. In this plot, impedance can be expressed by the real part ( $Z'$ ) or the modules  $|Z|$  and the phase shift  $\phi$



with respect to the imaginary part ( $Z''$ ) determined by the Randles circuit[48]. In the Randles circuit,  $R_{ct}$  is the charge transfer resistance,  $C_{dl}$  is capacitance of the dielectric layer, and  $Z_w$  is Warburg impedance[48]. As shown in Figure 6a, we plotted the Nyquist as a function of CYFRA-21-1 concentration. It was observed that the diameter of the semicircle increased with increasing concentration of CYFRA-21-1 (Figure 6a). We also drew the linearity graph between the  $R_{ct}$  value obtained from Randles circuit and the concentration of CYFRA-21-1 (Figure 6b). With increasing concentration, the  $R_{ct}$  value increased linearly from the log of  $0.01 \text{ ng}\cdot\text{mL}^{-1}$  to  $50 \text{ ng}\cdot\text{mL}^{-1}$ . This increase in  $R_{ct}$  was attributed to the insulating characteristics of the CYFRA-21-1 layer formed onto the BSA/anti-CYFRA-21-1/APTES/ $\text{nY}_2\text{O}_3$ /ITO immunoelectrode[49,50]. As the number of CYFRA-21-1 molecules increased, the  $F_{ab}$  region of anti-CYFRA-21-1 present on the immunoelectrodes became saturated due to binding of the paratope of CYFRA-21-1 on the antibodies. When the  $F_{ab}$  region of the immunoelectrode was saturated, CYFRA-21-1 did not bind with the immunoelectrode, hence we did not find any change in the  $R_{ct}$  value[49,50]. The linearity graph (Equation 9) indicated that the fabricated immunoelectrode could be utilized to measure the concentration of CYFRA-21-1 from 0.01 to  $50 \text{ ng}\cdot\text{mL}^{-1}$ .

$$I_p = [(0.23 \text{ K}\Omega\cdot\text{mL}\cdot\text{ng}^{-1}) \times \log \{\text{conc. of CYFRA-21-1 (ng mL}^{-1})\}] + 1.59, R^2 = 0.94 \quad (9)$$



**Figure 6.** (a) Nyquist plot for electrochemical impedometric response of the BSA/anti-CYFRA-21-1/APTES/ $\text{nY}_2\text{O}_3$ /ITO immunoelectrode on different concentrations of CYFRA-21-1 antigen. (b) Linearity graph obtained in between concentration of log [CYFRA-21-1 ( $\text{ng mL}^{-1}$ )] and charge transfer resistance ( $R_{ct}$ ). (c) Bar chart graph between different concentrations of CYFRA-21-1 and  $R_{ct}$  value obtained from electrochemical impedance response of APTES/ $\text{nY}_2\text{O}_3$ /ITO electrode with respect to various concentrations of CYFRA-21-1 by using Randles circuit. (d) Electrochemical impedometric response of the BSA/anti-CYFRA-21-1/APTES/ $\text{nY}_2\text{O}_3$ /ITO immunoelectrode with respect to various interferents present in saliva samples of cancer patients.

A control study was conducted via EIS to investigate the interaction of the APTES/ $\text{nY}_2\text{O}_3$ /ITO electrode with increasing CYFRA-21-1 concentration from  $0.01 \text{ ng}\cdot\text{mL}^{-1}$  to  $50 \text{ ng}\cdot\text{mL}^{-1}$ . The obtained  $R_{ct}$  values through Randles circuit were plotted as a function of CYFRA-21-1 concentration (Figure

6c). We did not observe any significant change in the  $R_{ct}$  value due to the APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode as a function of different concentrations of CYFRA-21-1 biomolecules. The observed electrochemical response revealed that the CYFRA-21-1 biomolecules did not interact with the APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode. The observed sensing characteristics were due to the interaction between antibodies immobilized onto the biosensing platform (BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO) and CYFRA-21-1 biomolecules.

We investigated the effect of various interferents present in real saliva samples of OC patients onto the EIS response of the fabricated biosensing electrode. In saliva samples, many analytes such as ET-1, CEA, glucose, NaCM cellulose, NaCl, KCl, CaCl<sub>2</sub>, cTn-I, etc. are known to be present [14]. We added these analytes into the PBS solution one-by-one, after which the EIS studies were conducted (Figure 6d). We did not find any significant changes on addition of analytes. The obtained results indicate that the fabricated immunoelectrode exhibited the EIS response towards CYFRA-21-1 biomolecules only. We checked the reproducibility of the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO biosensing electrode. In this study, we took eight different fabricated biosensing electrodes and measured both CV and EIS response. We found that deviation in the electrochemical response. The average percentage relative standard deviation (%RSD) was 5.4% and 2.1% in the CV and EIS response, respectively. The obtained results are shown in Figure S2. The shelf life of the developed biosensing electrode was measured by EIS in ferro-ferricyanide containing PBS buffer at regular intervals of one week to five weeks (Figure S3). We did not find any significant changes in the Nyquist plot, Randles circuit, or  $R_{ct}$  value, indicating that the immunoelectrode can be safely used for up to five weeks.

### 3.6. Oral Cancer Patient Samples Analysis

Concentration of CYFRA-21-1 biomarker present in salivary samples of seven different OC patients was estimated using a double sandwich ELISA technique. Thirty microliters of these biological saliva samples were used to estimate the CYFRA-21-1 concentration using the biosensing electrode (BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO), and results were correlated with ELISA (Table S2). The good correlation (average %RSD = 3.92%) between CYFRA-21-1 concentration obtained via the electrochemical impedance spectroscopy and ELISA techniques revealed that the developed biosensing platform could be efficiently used for the detection of salivary CYFRA-21-1 biomarker in OC patients. We also compared the biosensing characteristics of this biosensor with those reported in literature to date (Table 1). It can be seen that the fabricated biosensor is more efficient as compared to the reported biosensors for CYFRA-21-1 detection.

**Table 1.** Characteristics of the BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO-based biosensor, along with those reported in literature for oral cancer detection.

| Biomarker             | Labeled | Detection Technique | Materials Used               | Linear Detection Range         | Sensitivity                                         | Lower Detection Limit     | Ref. |
|-----------------------|---------|---------------------|------------------------------|--------------------------------|-----------------------------------------------------|---------------------------|------|
| has-miR-200a (mi-RNA) | Yes     | CV                  | Gold                         | 1 aM–10 fM                     | ----                                                | ----                      | [51] |
| CYFRA-21-1 (Protein)  | No      | CV                  | APTES/nZrO <sub>2</sub>      | 2–16 ng mL <sup>-1</sup>       | 2.2 $\mu$ A mL ng <sup>-1</sup>                     | 0.08 ng mL <sup>-1</sup>  | [14] |
|                       |         |                     | APTES/nHfO <sub>2</sub>      | 2–18 ng mL <sup>-1</sup>       | 9.28 $\mu$ A mL ng <sup>-1</sup> cm <sup>-2</sup>   | 0.21 ng mL <sup>-1</sup>  | [16] |
|                       |         |                     | APTES/nZrO <sub>2</sub> -RGO | 2–22 ng mL <sup>-1</sup>       | 0.756 $\mu$ A mL ng <sup>-1</sup>                   | 0.122 ng mL <sup>-1</sup> | [13] |
|                       |         | DPV                 | Serine/nZrO <sub>2</sub>     | 0.01–29 ng mL <sup>-1</sup>    | 0.295 $\mu$ A mL ng <sup>-1</sup>                   | 0.01 ng mL <sup>-1</sup>  | [15] |
|                       |         |                     | Cys-La(OH) <sub>3</sub>      | 0.001–10.2 ng mL <sup>-1</sup> | 12.044 $\mu$ A mL ng <sup>-1</sup> cm <sup>-2</sup> | 0.001 ng mL <sup>-1</sup> | [18] |
|                       |         |                     | APTES/nHfO <sub>2</sub> @RGO | 0–30 ng mL <sup>-1</sup>       | 18.24 $\mu$ A mL ng <sup>-1</sup>                   | 0.164 ng mL <sup>-1</sup> | [17] |

|     |                                      |                             |                                       |                             |                 |
|-----|--------------------------------------|-----------------------------|---------------------------------------|-----------------------------|-----------------|
| EIS | APTES/nY <sub>2</sub> O <sub>3</sub> | 0.01–50 ng mL <sup>-1</sup> | 226.0 $\Omega$ mL<br>ng <sup>-1</sup> | 0.33 ng<br>mL <sup>-1</sup> | Present<br>Work |
|-----|--------------------------------------|-----------------------------|---------------------------------------|-----------------------------|-----------------|

#### 4. Conclusions

The biocompatible and low dielectric constant nY<sub>2</sub>O<sub>3</sub> has been synthesized via solvothermal process and has been used for the fabrication of a label-free impedometric biosensor for saliva-based cancer detection. The fabricated BSA/anti-CYFRA-21-1/APTES/Y<sub>2</sub>O<sub>3</sub>/ITO immunoelectrode can be used to detect salivary CYFRA-21-1 in the linear range from 0.01 to 50 ng·mL<sup>-1</sup>, sensitivity of 226.0  $\Omega$ ·mL·ng<sup>-1</sup>, lower detection limit of 0.33 ng·mL<sup>-1</sup>, and shelf life of five weeks. It should be interesting to utilize the biocompatible nY<sub>2</sub>O<sub>3</sub> for the development of point-of-care devices, both for detection of communicable and non-communicable diseases.

**Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), **Figure S1:** (a) CV response of APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode as a function of scan rate (50–150 mV/s), (b) magnitude of anodic (I<sub>pa</sub>) and cathodic (I<sub>pc</sub>) peak current as a function of scan rate (mV/s) (c) difference potential  $\Delta E_p = E_{pa} - E_{pc}$  as function of scan rate, (d) CV response of BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO electrode as a function of scan rate (50–150 mV/s), (e) magnitude of anodic (I<sub>pa</sub>) and cathodic (I<sub>pc</sub>) peak current as a function of scan rate (mV/s) and (f) difference potential  $\Delta E_p = E_{pa} - E_{pc}$  as function of scan rate. **Figure S2:** Reproducibility studies of BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrode by using (a) CV and (b) EIS studies. **Figure S3:** Shelf life studies of BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrode via EIS studies. **Table S1:** % Cell viability of HEK 295 Cells with respect to various concentration of nY<sub>2</sub>O<sub>3</sub> along with % cell viability error bar (n=3). **Table S2:** Determination of CYFRA-21-1 concentration in saliva samples of oral cancer patient using BSA/anti-CYFRA-21-1/APTES/nY<sub>2</sub>O<sub>3</sub>/ITO immunoelectrodes.

**Author Contributions:** S.K. and B.D.M conceived and designed the experiments. S.K. and S.P. performed the experiments and analyzed the data. S.P wrote the initial draft. S.K., S.A., S.K., and B.D.M took part in discussions towards the review, editing and finalisations, of the manuscript.

**Funding:** This research received no external funding

**Acknowledgments:** We thank Yogesh Singh, Vice Chancellor, Delhi Technological University (DTU), Delhi, India for providing the facilities. Suveen Kumar and Saurabh Kumar are thankful to DST for the financial support (DST/INSPIRE/04/2017/001336 and DST/INSPIRE/04/2017/002750, respectively). Bansi D. Malhotra thanks the Science & Engineering Research Board (Govt. of India) for the award of a Distinguished Fellowship (SB/DF/011/2019).

**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

1. Warburg, O. On the origin of cancer cells. *Science* **1956**, *123*, 309–314.
2. Ecsedy, J.; Hunter, D. *The Origin of Cancer*; Oxford University Press: New York, NY, USA, 2002.
3. World Health Organization, Available online: <http://www.who.int/news-room/fact-sheets/detail/cancer>, (accessed on 25/11/2018).
4. Silverman, S. *Oral Cancer*; PMPH-USA: Raleigh, NC, USA, 2003; Volume 1.
5. Winn, D.M.; Blot, W.J.; Shy, C.M.; Pickle, L.W.; Toledo, A.; Fraumeni, J.F., Jr. Snuff dipping and oral cancer among women in the southern United States. *New Engl. J. Med.* **1981**, *304*, 745–749.
6. Patton, L.L.; Epstein, J.B.; Kerr, A.R. Adjunctive techniques for oral cancer examination and lesion diagnosis: A systematic review of the literature. *J. Am. Dent. Assoc.* **2008**, *139*, 896–905.
7. Rosenberg, D.; Cretin, S. Use of meta-analysis to evaluate total ionium chloride in oral cancer screening. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* **1989**, *67*, 621–627.
8. Neville, B.W.; Day, T.A. Oral cancer and precancerous lesions. *Ca A Cancer J. Clin.* **2002**, *52*, 195–215.
9. Alevizos, I.; Mahadevappa, M.; Zhang, X.; Ohyama, H.; Kohno, Y.; Posner, M.; Gallagher, G.T.; Varvares, M.; Cohen, D.; Kim, D. Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. *Oncogene* **2001**, *20*, 6196.

10. Yu, L.Q.; Wang, L.Y.; Su, F.H.; Hao, P.Y.; Wang, H.; Lv, Y.K. A gate-opening controlled metal-organic framework for selective solid-phase microextraction of aldehydes from exhaled breath of lung cancer patients. *Microchim. Acta* **2018**, *185*, 307.
11. Malhotra, R.; Urs, A.B.; Chakravarti, A.; Kumar, S.; Gupta, V.; Mahajan, B. Correlation of cyfra21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma. *Tumor Biol.* **2016**, *37*, 9263–9271.
12. Rajkumar, K.; Ramya, R.; Nandhini, G.; Rajashree, P.; Ramesh Kumar, A.; Nirmala Anandan, S. Salivary and serum level of cyfra21-1 in oral precancer and oral squamous cell carcinoma. *Oral Dis.* **2015**, *21*, 90–96.
13. Kumar, S.; Sharma, J.G.; Maji, S.; Malhotra, B.D. Nanostructured zirconia decorated reduced graphene oxide based efficient biosensing platform for non-invasive oral cancer detection. *Biosens. Bioelectron.* **2016**, *78*, 497–504.
14. Kumar, S.; Kumar, S.; Tiwari, S.; Srivastava, S.; Srivastava, M.; Yadav, B.K.; Kumar, S.; Tran, T.T.; Dewan, A.K.; Mulchandani, A. Biofunctionalized nanostructured zirconia for biomedical application: A smart approach for oral cancer detection. *Adv. Sci.* **2015**, *2*, 1500048.
15. Kumar, S.; Sharma, J.G.; Maji, S.; Malhotra, B.D. Abiocompatible serine functionalized nanostructured zirconia based biosensing platform for non-invasive oral cancer detection. *RSC Adv.* **2016**, *6*, 77037–77046.
16. Kumar, S.; Kumar, S.; Tiwari, S.; Augustine, S.; Srivastava, S.; Yadav, B.K.; Malhotra, B.D. Highly sensitive protein functionalized nanostructured hafnium oxide based biosensing platform for non-invasive oral cancer detection. *Sens. Actuators B Chem.* **2016**, *235*, 1–10.
17. Kumar, S.; Kumar, S.; Augustine, S.; Yadav, S.; Yadav, B.K.; Chauhan, R.P.; Dewan, A.K.; Malhotra, B.D. Effect of brownian motion on reduced agglomeration of nanostructured metal oxide towards development of efficient cancer biosensor. *Biosens. Bioelectron.* **2018**, *102*, 247–255.
18. Tiwari, S.; Gupta, P.K.; Bagbi, Y.; Sarkar, T.; Solanki, P.R. L-cysteine capped lanthanum hydroxide nanostructures for non-invasive detection of oral cancer biomarker. *Biosens. Bioelectron.* **2016**, *89*, 1042–1052.
19. Solanki, P.R.; Kaushik, A.; Agrawal, V.V.; Malhotra, B.D. Nanostructured metal oxide-based biosensors. *Npg Asia Mater.* **2011**, *3*, 17–24.
20. Tan, C.; Cao, X.; Wu, X.J.; He, Q.; Yang, J.; Zhang, X.; Chen, J.; Zhao, W.; Han, S.; Nam, G.H. Recent advances in ultrathin two-dimensional nanomaterials. *Chem. Rev.* **2017**, *117*, 6225–6331.
21. Kim, J.; Park, S.J.; Min, D.H. Emerging approaches for graphene oxide biosensor. *Anal. Chem.* **2016**, *89*, 232–248.
22. Thapa, A.; Soares, A.C.; Soares, J.C.; Awan, I.T.; Volpati, D.; Melendez, M.E.; Fregani, J.H.T.G.; Carvalho, A.L.; Oliveira Jr, O.N. Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker ca19-9. *ACS Appl. Mater. Interfaces* **2017**, *9*, 25878–25886.
23. Othman, A.; Karimi, A.; Andreescu, S. Functional nanostructures for enzyme based biosensors: Properties, fabrication and applications. *J. Mater. Chem. B* **2016**, *4*, 7178–7203.
24. Zhao, J.; Qin, L.; Hao, Y.; Guo, Q.; Mu, F.; Yan, Z. Application of tubular tetrapod magnesium oxide in a biosensor for hydrogen peroxide. *Microchim. Acta* **2012**, *178*, 439–445.
25. Shi, X.; Gu, W.; Li, B.; Chen, N.; Zhao, K.; Xian, Y. Enzymatic biosensors based on the use of metal oxide nanoparticles. *Microchim. Acta* **2014**, *181*, 1–22.
26. Xu, J.; Wang, Y.; Hu, S. Nanocomposites of graphene and graphene oxides: Synthesis, molecular functionalization and application in electrochemical sensors and biosensors. A review. *Microchim. Acta* **2017**, *184*, 1–44.
27. Kumar, S.; Ahlawat, W.; Kumar, R.; Dilbaghi, N. Graphene, carbon nanotubes, zinc oxide and gold as a sensitive nanomaterials for fabrication of biosensors for healthcare. *Biosens. Bioelectron.* **2015**, *70*, 498–503.
28. Hasanzadeh, M.; Shadjou, N.; de la Guardia, M. Iron and iron-oxide magnetic nanoparticles as signal-amplification elements in electrochemical biosensing. *Trac. Trends Anal. Chem.* **2015**, *72*, 1–9.
29. Luo, X.; Morrin, A.; Killard, A.J.; Smyth, M.R. Application of nanoparticles in electrochemical sensors and biosensors. *Electroanalysis* **2006**, *18*, 319–326.
30. Vasudev, A.; Kaushik, A.; Bhansali, S. Electrochemical immunosensor for label free epidermal growth factor receptor (EGFR) detection. *Biosens. Bioelectron.* **2013**, *39*, 300–305.
31. Campuzano, S.; Pedrero, M.; Nikoleli, G.P.; Pingarrón, J.; Nikolelis, D. Hybrid 2D-nanomaterials-based electrochemical immunosensing strategies for clinical biomarkers determination. *Biosens. Bioelectron.* **2017**, *89*, 269–279.
32. Solanki, S.; Pandey, C.M.; Soni, A.; Sumana, G.; Biradar, A.M. An amperometric bioenzymatic biosensor for the triglyceride tributyrin using an indium tin oxide electrode coated with electrophoretically deposited chitosan-wrapped nano zirconia. *Microchim. Acta* **2016**, *183*, 167–176.
33. Casero, E.; Alonso, C.; Petit-Domínguez, M.D.; Vázquez, L.; Parra-Alfambra, A.M.; Merino, P.; Álvarez-García, S.; de Andrés, A.; Suárez, E.; Pariente, F. Lactate biosensor based on a bio-nanocomposite composed of titanium oxide nanoparticles, photocatalytically reduced graphene, and lactate oxidase. *Microchim. Acta* **2014**, *181*, 79–87.



34. Huang, G.; Zhang, Lian, H.; Shizhu, Z.; Pengyue, Z.; Xianping, F. Synthesis of yttrium oxide nanocrystals via solvothermal process. *J. Rare Earths* **2006**, *24*, 47–50.
35. Li, N.; Yanagisawa, K. Yttrium oxide nanowires. In *Nanowires Science and Technology*; InTech: London, UK, 2010.
36. Tang, Q.; Liu, Z.; Li, S.; Zhang, S.; Liu, X.; Qian, Y. Synthesis of yttrium hydroxide and oxide nanotubes. *J. Cryst. Growth* **2003**, *259*, 208–214.
37. Curtis, C. Properties of yttrium oxide ceramics. *J. Am. Ceram. Soc.* **1957**, *40*, 274–278.
38. Razavi, R.S.; Ahsanzadeh-Vadeqani, M.; Barekat, M.; Naderi, M.; Hashemi, S.H.; Mishra, A.K. Effect of sintering temperature on microstructural and optical properties of transparent yttria ceramics fabricated by spark plasma sintering. *Ceram. Int.* **2016**, *42*, 7819–7823.
39. Mori, T.; Lee, J.H.; Li, J.; Ikegami, T.; Auchterlonie, G.; Drennan, J. Improvement of the electrolytic properties of  $\text{ZrO}_2$ -based materials using a crystallographic index. *Solid State Ion.* **2001**, *138*, 277–291.
40. Rasheed, P.A.; Radhakrishnan, T.; Shihabudeen, P.; Sandhyarani, N. Reduced graphene oxide–yttria nanocomposite modified electrode for enhancing the sensitivity of electrochemical genosensor. *Biosens. Bioelectron.* **2016**, *83*, 361–367.
41. Korotcenkov, G. Nanocomposites in electrochemical sensors. In *Handbook of Gas Sensor Materials*; Springer: Berlin/Heidelberg, Germany, 2014; pp. 223–235.
42. Tsutsumi, T. Dielectric properties of  $\text{ZrO}_2$  thin films prepared by vacuum evaporation. *Jpn. J. Appl. Phys.* **1970**, *9*, 735.
43. Dutta, P.K.; Szabo, N.F.; Du, H.; Akbar, S.A. Potentiometric nitric oxide sensors based on yttria-stabilized zirconia with the  $\text{ZrO}_2$  modified electrode. In Google Patents No. US6843900B2, 18 January 2005.
44. Pavia, D.L.; Lampman, G.M.; Kriz, G.S.; Vyvyan, J.A. *Introduction to Spectroscopy*; Cengage Learning: Boston, MA, USA, 2008.
45. Liu, G.; Lin, Y. Electrochemical sensor for organophosphate pesticides and nerve agents using zirconia nanoparticle as selective sorbent. *Anal. Chem.* **2005**, *77*, 5894–5901.
46. Kumar, S.; Kumar, S.; Augustine, S.; Malhotra, B.D. Protein functionalized nanostructured zirconia based electrochemical immunosensor for cardiac troponin detection. *J. Mater. Res.* **2017**, *32*, 2966–2972.
47. Xu, F.; Deng, M.; Li, G.; Chen, S.; Wang, L. Electrochemical behavior of cuprous oxide–reduced graphene oxide nanocomposites and their application in nonenzymatic hydrogen peroxide sensing. *Electrochim. Acta* **2013**, *88*, 59–65.
48. Orazem, M.E.; Tribollet, B. *Electrochemical Impedance Spectroscopy*; John Wiley & Sons: Hoboken, NJ, USA, 2011; Volume 48.
49. Srivastava, S.; Kumar, V.; Ali, M.A.; Solanki, P.R.; Srivastava, A.; Sumana, G.; Saxena, P.S.; Joshi, A.G.; Malhotra, B. Electrophoretically deposited reduced graphene oxide platform for food toxin detection. *Nanoscale* **2013**, *5*, 3043–3051.
50. Ali, M.A.; Singh, C.; Mondal, K.; Srivastava, S.; Sharma, A.; Malhotra, B.D. Mesoporous few-layer graphene platform for affinity biosensing application. *ACS Appl. Mater. Interfaces* **2016**, *8*, 7646–7656.
51. Wang, Z.; Zhang, J.; Guo, Y.; Wu, X.; Yang, W.; Xu, L.; Chen, J.; Fu, F. A novel electrically magnetic-controllable electrochemical biosensor for the ultrasensitive and specific detection of attomolar level of cancer-related microRNA. *Biosens. Bioelectron.* **2013**, *45*, 108–113.

